Lombard Odier

Status

Active

Total investments

28

Average round size

44M

Portfolio companies

24

Rounds per year

0.12

Lead investments

3

Follow on index

0.14

Exits

8

Areas of investment
BiotechnologyE-CommerceFinancial ServicesFinTechInformation TechnologyFinanceHealth CareHealth DiagnosticsPharmaceuticalTherapeutics

Summary

In 1796 was created Lombard Odier, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the Geneva. The company was established in Europe in Switzerland.

Among the most popular portfolio startups of the fund, we may highlight Fast Track, Hybrigenics, Simba Sleep. Among the most popular fund investment industries, there are Biotechnology, CRM. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.

Speaking about the real fund results, this Corporate Investor is 12 percentage points less often commits exit comparing to other organizations. This Lombard Odier works on 21 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2001. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2008. The fund is constantly included in less than 2 deals per year.

We also calculated 30 valuable employees in our database.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Lombard Odier, startups are often financed by Nigel Wray, Alta Partners, Tredegar Investments. The meaningful sponsors for the fund in investment in the same round are Alta Partners, JAFCO Asia, OrbiMed. In the next rounds fund is usually obtained by Alta Partners, Novartis Venture Fund, HBM Partners.

Show more

Investor highlights

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
28
Lead investments
3
Exits
8
Rounds per year
0.12
Follow on index
0.14
Investments by industry
  • Biotechnology (11)
  • Pharmaceutical (6)
  • Financial Services (4)
  • FinTech (4)
  • Health Care (4)
  • Show 46 more
Investments by region
  • United States (12)
  • Germany (3)
  • France (4)
  • United Kingdom (5)
  • Brazil (1)
  • Show 2 more
Peak activity year
2022

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
14
Avg. valuation at time of investment
72M
Group Appearance index
0.89
Avg. company exit year
10
Avg. multiplicator
2.48
Strategy success index
0.20

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
900.care 26 Mar 2024 Consumer Goods, Personal Health Early Stage Venture 24M Ile-de-France, Paris, France
Agensys 04 Mar 2002 Biotechnology, Health Diagnostics, Pharmaceutical Late Stage Venture 42M United States, California, Santa Monica
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.